Shandong Xinhua Pharmaceutical (000756.SZ) obtained the drug registration certificate for Levocarnitine Oral Solution.
Shandong Xinhua Pharmaceutical (000756.SZ) announced that recently, the company received the Drug Registration Certificate for Levocarnitine Oral Solution (hereinafter referred to as "this product") approved and issued by the National Medical Products Administration. This product is used for the treatment of primary systemic carnitine deficiency. In reported cases, clinical manifestations include recurrent Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy.
Shandong Xinhua Pharmaceutical (000756.SZ) announced that recently, the company received the "Drug Registration Certificate" for Levocarnitine Oral Solution (hereinafter referred to as "this product") approved and issued by the National Medical Products Administration. This product is used for the treatment of primary systemic carnitine deficiency. In reported cases, clinical manifestations include recurrent Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy.
Related Articles
Beijing Huayuan Xinhang Holding (600743.SH)'s controlling shareholder is proposed to be changed to Financial Street Holdings Capital.
Shenzhen Techwinsemi Technology (001309.SZ)'s application for additional stock issuance has been approved by the Listing Review Center of the Shenzhen Stock Exchange.
Anhui Honglu Steel Construction (002541.SZ) subsidiary signs major business contract, with an estimated contract value of approximately 280 million yuan.
Beijing Huayuan Xinhang Holding (600743.SH)'s controlling shareholder is proposed to be changed to Financial Street Holdings Capital.
Shenzhen Techwinsemi Technology (001309.SZ)'s application for additional stock issuance has been approved by the Listing Review Center of the Shenzhen Stock Exchange.
Anhui Honglu Steel Construction (002541.SZ) subsidiary signs major business contract, with an estimated contract value of approximately 280 million yuan.
RECOMMEND
